Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-course Pretomanid Regimen (BPaLM) for RR-TB in China
NCT07126639Not yet recruiting
- Sponsor
- Wuhan Pulmonary Hospital
- Start
- Sep 2025
- Primary completion
- Sep 2027
- Modality
- Prodrugs/Conditional Activator Small Molecules
01
Overview
Randomised, open-label trial of pretomanid in Tuberculosis (TB) (2 arms), sponsored by Wuhan Pulmonary Hospital. Primary endpoint: Favorable outcomes during the treatment period at 28 weeks. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
pretomanid
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT07126639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07126639.